Publication date: Jul 24, 2019 Uveal melanoma is the most common primary intraocular malignancy among adults. It is, nevertheless, a rare disease, with an incidence of approximately one case per ... Read more

Publication date: Feb 18, 2019 Recent advances in the development of immunotherapy drugs have resulted in durable responses and improved overall survival for a proportion of patients with advanced melanoma; ... Read more

Publication date: Feb 18, 2019 Recent advances in the development of immunotherapy drugs have resulted in durable responses and improved overall survival for a proportion of patients with advanced melanoma; ... Read more

Publication date: Jan 14, 2019 Tumour immunotherapy, and particularly immue checkpoint inhibitors, have resulted in considerable response rates in patients with metastatic cancer. However, most of these approaches are limited ... Read more

Publication date: Sep 06, 2018 Immune checkpoint blockade (ICB) and BRAF-targeted therapy have demonstrated substantial clinical efficacy for patients with stage 4 melanoma in clinical trials; however, their impact on ... Read more

Publication date: Jul 12, 2018 The successes of checkpoint blockade immunotherapy (CBI) and BRAF-targeted therapy trials have generated substantial promise for revolutionizing the management of patients with advanced melanoma. However, ... Read more

Publication date: Jun 14, 2018 The treatment options for metastatic malignant melanoma have drastically changed recently,including the increased use of immunotherapeutic agents that offer significant responses. Accordingly, it hasbecome common ... Read more